Previous 10 | Next 10 |
Gainers : Rexahn Pharmaceuticals (NYSEMKT: RNN ) +28% . UP Fintech Holding (NASDAQ: TIGR ) +21% . Iconix Brand Group (NASDAQ: ICON ) +22% . ReWalk Robotics (NASDAQ: RWLK ) +16% . Future FinTech Group (NASDAQ: FTFT ) +13% . 360 Finance (NASDAQ: QFIN ) +13% . FTS International (NY...
scPharmaceuticals (NASDAQ: SCPH ): Q4 GAAP EPS of -$0.27 beats by $0.18. More news on: scPharmaceuticals Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Signed development agreement with West Pharmaceutical Services for next-generation FUROSCIX ® On-Body Infusor Resubmission of FURSOCIX with the U.S. Food and Drug Administration (FDA) by year-end 2020 Balance sheet remains strong with over $89 million in cash BURLINGTON, ...
BURLINGTON, Mass., Feb. 21, 2019 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs, to...
Amicus Therapeutics (NASDAQ: FOLD ) initiated with Overweight rating and $20 (76% upside) price target at Cantor Fitzgerald. Shares up 2% premarket. More news on: Amicus Therapeutics, Inc., Intercept Pharmaceuticals, Allergan plc, Healthcare stocks news, Stocks on the move, , ...
Gainers: OncoCyte (NYSEMKT: OCX ) +228% . Voyager Therapeutics (NASDAQ: VYGR ) +36% . Conatus Pharmaceuticals (NASDAQ: CNAT ) +34% . Zynerba Pharmaceuticals (NASDAQ: ZYNE ) +33% . HyreCar (NASDAQ: HYRE ) +21% . Sanmina (NASDAQ: SANM ) +18% . Woodward (NASDAQ: WWD ) +17% . J &a...
ScPharmaceuticals ( SCPH +5.4% ) inks an agreement with West Pharmaceutical Services ( WST -0.3% ) aimed at incorporating the latter's SmartDose Drug Delivery System with the former's lead drug FUROSCIX (furosemide), in development for treating edema in heart failure patients. More...
Advancing FUROSCIX ® with the SmartDose ® Drug Delivery System Forecast 2018 year-end cash of $82 - $87 million and 2019 expenditures of $8 - $10 million per quarter BURLINGTON, Mass., Jan. 29, 2019 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH)...
On Tuesday, Aug. 14, scPharmaceuticals ( SCPH ) presented its quarterly update, reporting a net loss of $9.9 million in Q2 - just better than analyst predictions. That said, the company still has a strong cash position of $101 million, which management believes is enough to finance operation...
Request for Type A meeting was granted by the U.S. Food and Drug Administration to discuss the Complete Response Letter received in June 2018 Balance sheet remains strong with over $100 million in cash BURLINGTON, Mass., Aug. 14, 2018 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasd...
News, Short Squeeze, Breakout and More Instantly...
scPharmaceuticals Inc. Company Name:
SCPH Stock Symbol:
NASDAQ Market:
scPharmaceuticals Inc. Website:
BURLINGTON, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today an...
A look at the top 10 most actives in the United States SiNtx Technologies Inc. (SINT) rose 208.7% to $0.1698 on volume of 325,435,783 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 76.7% to $0.5039 on volume of 314,353,673 shares Greenwave Technology Solutions Inc. (GWAV) ros...
Generated 1Q 2024 net FUROSCIX ® revenue of $6.1 million, despite an estimated 10% impact to doses filled resulting from the Change Healthcare cyberattack Ended 1Q 2024 with cash and cash equivalents o f $58.4 million Company to host investor conference call and web...